Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya
BACKGROUND:In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Market Commitment, which helped countries access more affordable pneumococcal vaccines. As many low-income countries begin to reach the threshold at which countries transition from Gavi support to self-financing (...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2019
|
| _version_ | 1797080510766252032 |
|---|---|
| author | Ojal, J Griffiths, U Hammitt, L Adetifa, I Akech, D Tabu, C Scott, J Flasche, S |
| author_facet | Ojal, J Griffiths, U Hammitt, L Adetifa, I Akech, D Tabu, C Scott, J Flasche, S |
| author_sort | Ojal, J |
| collection | OXFORD |
| description | BACKGROUND:In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Market Commitment, which helped countries access more affordable pneumococcal vaccines. As many low-income countries begin to reach the threshold at which countries transition from Gavi support to self-financing (3-year average gross national income per capita of US$1580), they will need to consider whether to continue pneumococcal conjugate vaccine (PCV) use at full cost or to discontinue PCV in their childhood immunisation programmes. Using Kenya as a case study, we assessed the incremental cost-effectiveness of continuing PCV use. METHODS:In this modelling and cost-effectiveness study, we fitted a dynamic compartmental model of pneumococcal carriage to annual carriage prevalence surveys and invasive pneumococcal disease (IPD) incidence in Kilifi, Kenya. We predicted disease incidence and related mortality for either continuing PCV use beyond 2022, the start of Kenya's transition from Gavi support, or its discontinuation. We calculated the costs per disability-adjusted life-year (DALY) averted and associated 95% prediction intervals (PI). FINDINGS:We predicted that if PCV use is discontinued in Kenya in 2022, overall IPD incidence will increase from 8·5 per 100 000 in 2022, to 16·2 per 100 000 per year in 2032. Continuing vaccination would prevent 14 329 (95% PI 6130-25 256) deaths and 101 513 (4386-196 674) disease cases during that time. Continuing PCV after 2022 will require an estimated additional US$15·8 million annually compared with discontinuing vaccination. We predicted that the incremental cost per DALY averted of continuing PCV would be $153 (95% PI 70-411) in 2032. INTERPRETATION:Continuing PCV use is essential to sustain its health gains. Based on the Kenyan GDP per capita of $1445, and in comparison to other vaccines, continued PCV use at full costs is cost-effective (on the basis of the assumption that any reduction in disease will translate to a reduction in mortality). Although affordability is likely to be a concern, our findings support an expansion of the vaccine budget in Kenya. FUNDING:Wellcome Trust and Gavi, the Vaccine Alliance. |
| first_indexed | 2024-03-07T01:01:08Z |
| format | Journal article |
| id | oxford-uuid:89c751f7-70aa-4c66-8f64-d61205fafb58 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:01:08Z |
| publishDate | 2019 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:89c751f7-70aa-4c66-8f64-d61205fafb582022-03-26T22:26:52ZSustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in KenyaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:89c751f7-70aa-4c66-8f64-d61205fafb58EnglishSymplectic Elements at OxfordElsevier2019Ojal, JGriffiths, UHammitt, LAdetifa, IAkech, DTabu, CScott, JFlasche, SBACKGROUND:In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Market Commitment, which helped countries access more affordable pneumococcal vaccines. As many low-income countries begin to reach the threshold at which countries transition from Gavi support to self-financing (3-year average gross national income per capita of US$1580), they will need to consider whether to continue pneumococcal conjugate vaccine (PCV) use at full cost or to discontinue PCV in their childhood immunisation programmes. Using Kenya as a case study, we assessed the incremental cost-effectiveness of continuing PCV use. METHODS:In this modelling and cost-effectiveness study, we fitted a dynamic compartmental model of pneumococcal carriage to annual carriage prevalence surveys and invasive pneumococcal disease (IPD) incidence in Kilifi, Kenya. We predicted disease incidence and related mortality for either continuing PCV use beyond 2022, the start of Kenya's transition from Gavi support, or its discontinuation. We calculated the costs per disability-adjusted life-year (DALY) averted and associated 95% prediction intervals (PI). FINDINGS:We predicted that if PCV use is discontinued in Kenya in 2022, overall IPD incidence will increase from 8·5 per 100 000 in 2022, to 16·2 per 100 000 per year in 2032. Continuing vaccination would prevent 14 329 (95% PI 6130-25 256) deaths and 101 513 (4386-196 674) disease cases during that time. Continuing PCV after 2022 will require an estimated additional US$15·8 million annually compared with discontinuing vaccination. We predicted that the incremental cost per DALY averted of continuing PCV would be $153 (95% PI 70-411) in 2032. INTERPRETATION:Continuing PCV use is essential to sustain its health gains. Based on the Kenyan GDP per capita of $1445, and in comparison to other vaccines, continued PCV use at full costs is cost-effective (on the basis of the assumption that any reduction in disease will translate to a reduction in mortality). Although affordability is likely to be a concern, our findings support an expansion of the vaccine budget in Kenya. FUNDING:Wellcome Trust and Gavi, the Vaccine Alliance. |
| spellingShingle | Ojal, J Griffiths, U Hammitt, L Adetifa, I Akech, D Tabu, C Scott, J Flasche, S Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya |
| title | Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya |
| title_full | Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya |
| title_fullStr | Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya |
| title_full_unstemmed | Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya |
| title_short | Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya |
| title_sort | sustaining pneumococcal vaccination after transitioning from gavi support a modelling and cost effectiveness study in kenya |
| work_keys_str_mv | AT ojalj sustainingpneumococcalvaccinationaftertransitioningfromgavisupportamodellingandcosteffectivenessstudyinkenya AT griffithsu sustainingpneumococcalvaccinationaftertransitioningfromgavisupportamodellingandcosteffectivenessstudyinkenya AT hammittl sustainingpneumococcalvaccinationaftertransitioningfromgavisupportamodellingandcosteffectivenessstudyinkenya AT adetifai sustainingpneumococcalvaccinationaftertransitioningfromgavisupportamodellingandcosteffectivenessstudyinkenya AT akechd sustainingpneumococcalvaccinationaftertransitioningfromgavisupportamodellingandcosteffectivenessstudyinkenya AT tabuc sustainingpneumococcalvaccinationaftertransitioningfromgavisupportamodellingandcosteffectivenessstudyinkenya AT scottj sustainingpneumococcalvaccinationaftertransitioningfromgavisupportamodellingandcosteffectivenessstudyinkenya AT flasches sustainingpneumococcalvaccinationaftertransitioningfromgavisupportamodellingandcosteffectivenessstudyinkenya |